Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1977 3
1978 1
1979 2
1980 3
1981 6
1982 8
1983 8
1984 12
1985 12
1986 19
1987 34
1988 28
1989 35
1990 32
1991 34
1992 51
1993 56
1994 45
1995 49
1996 61
1997 72
1998 70
1999 53
2000 72
2001 66
2002 84
2003 78
2004 76
2005 82
2006 79
2007 87
2008 123
2009 124
2010 129
2011 145
2012 142
2013 175
2014 185
2015 187
2016 207
2017 209
2018 202
2019 228
2020 279
2021 321
2022 297
2023 262
2024 99

Text availability

Article attribute

Article type

Publication date

Search Results

4,140 results

Results by year

Citations

4 articles found by citation matching
Show all

Search results

Filters applied: . Clear all
Page 1
Precision medicine in acute lymphoblastic leukemia.
Pui CH. Pui CH. Front Med. 2020 Dec;14(6):689-700. doi: 10.1007/s11684-020-0759-8. Epub 2020 Oct 19. Front Med. 2020. PMID: 33074527 Free PMC article. Review.
The cure rate of childhood acute lymphoblastic leukemia (ALL) has exceeded 90% in some contemporary clinical trials. ...BH3 profiling and other preclinical methods have identified several high-risk subtypes, such as hypodiplod, early T-cell …
The cure rate of childhood acute lymphoblastic leukemia (ALL) has exceeded 90% in some contemporary clinical trials. .. …
Next-Generation Sequencing in Acute Lymphoblastic Leukemia.
Coccaro N, Anelli L, Zagaria A, Specchia G, Albano F. Coccaro N, et al. Int J Mol Sci. 2019 Jun 15;20(12):2929. doi: 10.3390/ijms20122929. Int J Mol Sci. 2019. PMID: 31208040 Free PMC article. Review.
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and accounts for about a quarter of adult acute leukemias, and features different outcomes depending on the age of onset. ...Lastly, we consider the need for the integration of NGS …
Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and accounts for about a quarter of adult acu …
Lymphoblastic Lymphoma: a Concise Review.
Intermesoli T, Weber A, Leoncin M, Frison L, Skert C, Bassan R. Intermesoli T, et al. Curr Oncol Rep. 2022 Jan;24(1):1-12. doi: 10.1007/s11912-021-01168-x. Epub 2022 Jan 20. Curr Oncol Rep. 2022. PMID: 35059993 Review.
PURPOSE OF REVIEW: Lymphoblastic lymphoma (LBL) is a rare, highly aggressive non-Hodgkin lymphoma variant virtually indistinguishable from acute lymphoblastic leukemia (ALL). ...Stem cell transplantation is effective and should be considered for …
PURPOSE OF REVIEW: Lymphoblastic lymphoma (LBL) is a rare, highly aggressive non-Hodgkin lymphoma variant virtually indistinguishable …
Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients.
Saygin C, Cannova J, Stock W, Muffly L. Saygin C, et al. Haematologica. 2022 Dec 1;107(12):2783-2793. doi: 10.3324/haematol.2022.280638. Haematologica. 2022. PMID: 36453516 Free PMC article.
Measurable residual disease (MRD) is the most powerful independent predictor of risk of relapse and long-term survival in adults and children with acute lymphoblastic leukemia (ALL). For almost all patients with ALL there is a reliable method to …
Measurable residual disease (MRD) is the most powerful independent predictor of risk of relapse and long-term survival in adults and …
Acute lymphoblastic leukaemia.
Harrison CJ. Harrison CJ. Best Pract Res Clin Haematol. 2001 Sep;14(3):593-607. doi: 10.1053/beha.2001.0156. Best Pract Res Clin Haematol. 2001. PMID: 11640871 Review.
In acute lymphoblastic leukaemia (ALL) the karyotype provides important prognostic information which is beginning to have an impact on treatment. ...Numerical chromosomal abnormalities are of particular importance in relation to prognosis. High hyperdi …
In acute lymphoblastic leukaemia (ALL) the karyotype provides important prognostic information which is beginning to ha …
Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia.
Harvey RC, Tasian SK. Harvey RC, et al. Blood Adv. 2020 Jan 14;4(1):218-228. doi: 10.1182/bloodadvances.2019000163. Blood Adv. 2020. PMID: 31935290 Free PMC article. Review.
Philadelphia chromosome-like B-cell acute lymphoblastic leukemia (Ph-like ALL) accounts for 15% to 30% of B-cell acute lymphoblastic leukemia in older children, adolescents, and adults and is associated with high rate …
Philadelphia chromosome-like B-cell acute lymphoblastic leukemia (Ph-like ALL) accounts for 15% to 30% of B-c …
Who Should Receive a Transplant for Acute Lymphoblastic Leukaemia?
Dhawan R, Marks DI. Dhawan R, et al. Curr Hematol Malig Rep. 2017 Apr;12(2):143-152. doi: 10.1007/s11899-017-0371-4. Curr Hematol Malig Rep. 2017. PMID: 28215040 Review.
Allogeneic haematopoietic cell transplantation continues to be an important curative therapy for acute lymphoblastic leukaemia (ALL). ...We also discuss how alternative donors, haploidentical and cord blood and reduced intensity conditioning make allog …
Allogeneic haematopoietic cell transplantation continues to be an important curative therapy for acute lymphoblastic …
Which patients should I transplant with acute lymphoblastic leukemia?
Inbar T, Rowe JM, Horowitz NA. Inbar T, et al. Best Pract Res Clin Haematol. 2017 Sep;30(3):249-260. doi: 10.1016/j.beha.2017.07.005. Epub 2017 Jul 13. Best Pract Res Clin Haematol. 2017. PMID: 29050698 Review.
Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia (ALL) offers curative therapy for patients who are in complete remission. Historically, there was great hesitation to offer this modality to patients with ALL …
Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia (ALL) offers curative therapy for …
Clinically defining and managing high-risk pediatric patients with acute lymphoblastic leukemia.
Alexander S. Alexander S. Hematology Am Soc Hematol Educ Program. 2014 Dec 5;2014(1):181-9. doi: 10.1182/asheducation-2014.1.181. Epub 2014 Nov 18. Hematology Am Soc Hematol Educ Program. 2014. PMID: 25696853 Review.
For children with acute lymphoblastic leukemia, the identification of those at higher risk of disease recurrence and modifying therapy based on this risk is a critical component to the provision of optimal care. ...Intensification of conventiona …
For children with acute lymphoblastic leukemia, the identification of those at higher risk of disease recurrence …
Aberrant IKZF1 gene as relapse predictor in standard-risk pediatric patients with B-cell precursor acute lymphoblastic leukaemia.
Vshyukova VS, Krasko OV, Yanchanka DA, Meleshko AN. Vshyukova VS, et al. Int J Lab Hematol. 2022 Aug;44(4):769-776. doi: 10.1111/ijlh.13853. Epub 2022 May 3. Int J Lab Hematol. 2022. PMID: 35505470
INTRODUCTION: Worldwide, the B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) treatment protocols are based on risk-adaptive therapy, that is on the search for biological markers for stratification by risk groups for optima …
INTRODUCTION: Worldwide, the B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) treatment protocols …
4,140 results